BRNS

Barinthus Biotherapeutics plc (BRNS) | Rumor.io

Barinthus Biotherapeutics

BRNS

Attention (50-day avg)0%

Attention rank (50-day avg)#3,831

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.45

Market capitalization30.2M

Earnings per share-1.02

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-66.5M

Social

What share of all stock conversation is about BRNS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Sep 30

Barinthus Biotherapeutics (BRNS) has entered a definitive all-stock merger agreement with Clywedog Therapeutics to form a combined company, which will focus on advancing therapies in immunology, inflammation, and diabetes.
The merger may initiate a partial tender offer to purchase up to $27M worth of outstanding shares before the transaction closes.
Analysts estimate the post-merger price of BRNS to be around $1.30 per share, based on the combined company's value and potential assets, including existing VTP-1000 in Celiac and three Phase 2-ready trials in diabetes.

Generated by AI

Sentiment

Of the messages about BRNS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.6% +2.35
Bearish	—	—	—	10.4% -2.35

Bullish· Jul 16

The company's immunotherapy for celiac disease, VTP-1000, is in the clinic and expected to report Phase 1 data in Q3 2025.
The stock has a strong short-term debt repayment ability, with a current ratio of 8.96 and cash reserves of $106 million.
The stock price has shown significant growth, soaring from a low of $1.00 to a high of $2.92, with insiders loading up on the stock and a potential catalyst for further growth.

Bearish· Jul 16

$BRNS has been involved in a pump and dump scheme, with prices inflated from $1.80 to $2.93 and then dumped back down.
The asset's price movement has been unpredictable and difficult to trade, making it hard to determine its value.
Investors who bought $BRNS at higher prices are now facing significant losses, with some users expressing regret and frustration over their investment decisions.

Generated by AI

Topics

Of the messages about BRNS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	88.04%
Technical Analysis	—	—	0%	9.78%
Analysts	—	—	0%	0%
Controversies	—	—	0%	2.17%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Sep 30

Barinthus Biotherapeutics (BRNS) has entered a definitive agreement to merge with Clywedog Therapeutics in an all-stock transaction to form a combined company that will focus on advancing therapies in immunology, inflammation, and diabetes.
The combined company will have a portfolio that includes three clinical-stage product candidates targeting major diseases, with four clinical data milestones expected within 18 months of the transaction.
The merger is expected to close in the first half of 2026, with the combined company supported by existing cash and additional investments from existing and new shareholders.

Generated by AI

Community

Of the messages about BRNS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	6.9%	29.37%
Newcomers	100%	100%	93.1%	70.63%

News

Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?

Here is how Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) and Agilent Technologies (A) have performed compared to their sector so far this year.

22d agoYahoo Finance

Barinthus Biotherapeutics advances court-approved merger, Nasdaq exit

Detailed price information for Barinthus Biotherapeutics Plc ADR (BRNS-Q) from The Globe and Mail including charting and trades.

27d agoThe Globe and Mail

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreementScheme of arrangement expected to become effective on September 3,...

1mo agoBarchart.com

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

1mo agoYahoo Finance

12 Health Care Stocks Moving In Monday's Intraday Session - Zhengye Biotechnology (NASDAQ:ZYBT), Advanced

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million. Advanced Biomed (NASDAQ:ADVB) stock moved

2mo agoBenzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session - Advanced Biomed (NASDAQ:ADVB), Barinthus Bi

Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares

2mo agoBenzinga

Also Discussed

Investors talking about BRNS also mention

#	Name	Attention
1	Above Food Ingredients Inc.ABVE	0%new
2	AEye, Inc. Class A Common StockLIDR	0%0
3	Roivant Sciences Ltd.ROIV	0%new
4	Intellinetics Inc.INLX	0%0
5	Cryo-Cell International, Inc.CCEL	0%0
6	Ark Restaurants Corp.ARKR	0%0
7	Arbutus Biopharma CorporationABUS	0%0
8	Vera Therapeutics Inc.VERA	0%new
9	Natural Health Trends Corp.NHTC	0%0
10	Investcorp Credit Management BDC, Inc.ICMB	0%new

Barinthus Biotherapeutics plc

Healthcare
Biotechnology

Barinthus Biotherapeutics plc American Depositary Shares is a biopharmaceutical security representing ownership in Barinthus Biotherapeutics plc, a clinical-stage company focused on immunology and inflammation. The company develops antigen-specific immunotherapeutic candidates designed to guide T cells in addressing chronic infectious diseases, autoimmune conditions, and cancer. Its current programs span therapeutic and prophylactic research in areas such as autoimmunity, inflammatory disorders, and infectious disease, reflecting a pipeline centered on immune-system modulation. Barinthus Biotherapeutics serves the biotechnology market through the development of biologic candidates intended for clinical evaluation and potential future commercialization. The American Depositary Shares provide U.S. investors with access to the company’s ordinary shares while the underlying business remains centered in the United Kingdom. Barinthus Biotherapeutics plc is headquartered in Didcot, Oxfordshire, United Kingdom.

Website

Location

20400 Century Boulevard

Germantown, MD, 20874

United States

Social

What share of all stock conversation is about BRNS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Sep 30

Barinthus Biotherapeutics (BRNS) has entered a definitive all-stock merger agreement with Clywedog Therapeutics to form a combined company, which will focus on advancing therapies in immunology, inflammation, and diabetes.
The merger may initiate a partial tender offer to purchase up to $27M worth of outstanding shares before the transaction closes.
Analysts estimate the post-merger price of BRNS to be around $1.30 per share, based on the combined company's value and potential assets, including existing VTP-1000 in Celiac and three Phase 2-ready trials in diabetes.

Generated by AI

Sentiment

Of the messages about BRNS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.6% +2.35
Bearish	—	—	—	10.4% -2.35

Bullish· Jul 16

The company's immunotherapy for celiac disease, VTP-1000, is in the clinic and expected to report Phase 1 data in Q3 2025.
The stock has a strong short-term debt repayment ability, with a current ratio of 8.96 and cash reserves of $106 million.
The stock price has shown significant growth, soaring from a low of $1.00 to a high of $2.92, with insiders loading up on the stock and a potential catalyst for further growth.

Bearish· Jul 16

$BRNS has been involved in a pump and dump scheme, with prices inflated from $1.80 to $2.93 and then dumped back down.
The asset's price movement has been unpredictable and difficult to trade, making it hard to determine its value.
Investors who bought $BRNS at higher prices are now facing significant losses, with some users expressing regret and frustration over their investment decisions.

Generated by AI

Topics

Of the messages about BRNS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	88.04%
Technical Analysis	—	—	0%	9.78%
Analysts	—	—	0%	0%
Controversies	—	—	0%	2.17%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%

Sep 30

Barinthus Biotherapeutics (BRNS) has entered a definitive agreement to merge with Clywedog Therapeutics in an all-stock transaction to form a combined company that will focus on advancing therapies in immunology, inflammation, and diabetes.
The combined company will have a portfolio that includes three clinical-stage product candidates targeting major diseases, with four clinical data milestones expected within 18 months of the transaction.
The merger is expected to close in the first half of 2026, with the combined company supported by existing cash and additional investments from existing and new shareholders.

Generated by AI

Community

Of the messages about BRNS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	6.9%	29.37%
Newcomers	100%	100%	93.1%	70.63%

Barinthus Biotherapeutics

Social

Sep 30

Bullish· Jul 16

Bearish· Jul 16

Sep 30

Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?

Barinthus Biotherapeutics advances court-approved merger, Nasdaq exit

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

12 Health Care Stocks Moving In Monday's Intraday Session - Zhengye Biotechnology (NASDAQ:ZYBT), Advanced

12 Health Care Stocks Moving In Monday's Pre-Market Session - Advanced Biomed (NASDAQ:ADVB), Barinthus Bi

Also Discussed

Barinthus Biotherapeutics plc

Company Information

Location

Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?

Barinthus Biotherapeutics advances court-approved merger, Nasdaq exit

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

12 Health Care Stocks Moving In Monday's Intraday Session - Zhengye Biotechnology (NASDAQ:ZYBT), Advanced

12 Health Care Stocks Moving In Monday's Pre-Market Session - Advanced Biomed (NASDAQ:ADVB), Barinthus Bi

Also Discussed

Social

Sep 30

Bullish· Jul 16

Bearish· Jul 16

Sep 30